Small Airway Disease And Bronchial Hyperreactivity In Patients With Post Acute Covid-19 Syndrome

April 18, 2024 updated by: Tamer Awad, Mansoura University
The aim of this work is to estimate the frequency of small airway disease and/or the bronchial hyperreactivity in follow up of postacute covid survivors.

Study Overview

Status

Completed

Conditions

Detailed Description

This is a observational longitudinal study investigating pulmonary sequelae of covid-19.

Study site:

Mansoura university hospital, chest department and post covid outpatient clinic.

Elmahalla chest hospital and outpatients clinic.

Time of study :

Two years from September 2021 to September 2023

Target population:

Adults with confirmed covid 19 who remaining symptomatic after 30 days from the diagnosis.

Sample size The study will include 100 selected cases during period from 2021 to 2023

Patients :

The enrolled patients are adults who survived acute covid-19 and presented for clinical follow up.

Study Type

Observational

Enrollment (Actual)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
    • Dakhlia
      • Mansoura, Dakhlia, Egypt, 050
        • Mansoura University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Adults with confirmed covid 19 who remaining symptomatic after 30 days from the diagnosis.

Description

Inclusion Criteria:

  • Ambulatory adult patients confirmed diagnosis of covid -19 either on typical CT chest basis or PCR and passed period of acute illness (28 days from start of symptoms) but still with clinical symptoms.

Exclusion Criteria:

  • Hospitalized or requiring intensive care unit. Known patients with chronic lung diseases Uncontrolled comorbidities

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
investigating pulmonary sequelae of covid-19.
Time Frame: 3moth
The selected post covid patients on the day of their clinic visit (one to three months after being diagnosed covid 19
3moth
investigating pulmonary sequelae of covid-19.
Time Frame: 6 month
The selected post covid patients on the day of their clinic visit (6 months after being diagnosed covid 19
6 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mansoura University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2021

Primary Completion (Actual)

September 1, 2023

Study Completion (Actual)

April 1, 2024

Study Registration Dates

First Submitted

April 16, 2024

First Submitted That Met QC Criteria

April 16, 2024

First Posted (Actual)

April 18, 2024

Study Record Updates

Last Update Posted (Actual)

April 19, 2024

Last Update Submitted That Met QC Criteria

April 18, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MD.21.11.564

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe